贝伐珠单抗联合化疗对比单纯化疗一线治疗老年转移性结直肠癌:随机II期PRODIGE 20研究
PRODIGE 20研究将≥75岁未经治疗的转移性结直肠癌患者随机分为贝伐珠单抗联合化疗组(BEV)与单纯化疗组(CT),评估4个月时的复合主要终点(疗效与安全性)。结果显示两组均达到预设的疗效与安全性阈值,BEV组与CT组的中位PFS分别为9.7个月与7.8个月,中位OS分别为21.7个月与19.8个月。
要点
- ≥75岁转移性结直肠癌患者中,贝伐珠单抗联合化疗与单纯化疗均达到预设疗效与安全性标准。
- BEV组与CT组4个月时达到疗效标准的比例分别为50%与58%,达到安全性标准的比例分别为61%与71%。
- BEV组与CT组中位PFS分别为9.7个月与7.8个月,中位OS分别为21.7个月与19.8个月。
核心结论
- 贝伐珠单抗联合化疗在老年转移性结直肠癌患者中是安全且有效的,两组均达到主要安全性及疗效标准。
研究设计与样本
- 随机II期PRODIGE 20研究,纳入≥75岁未经治疗的转移性结直肠癌患者,随机分为贝伐珠单抗联合化疗组(BEV,51例)与单纯化疗组(CT,51例),共102例。
- 化疗方案为LV5FU2、FOLFOX或FOLFIRI,由研究者选择。
- 复合共同主要终点于随机后4个月评估,基于疗效(肿瘤控制且Spitzer生活质量指数未下降)与安全性(无严重心血管毒性且无意外住院)。
- 预设判定标准:若≤20%患者满足疗效标准则视为无效,若≤40%患者满足安全性标准则视为不安全。
主要发现
- 4个月时达到疗效标准的患者比例:BEV组50% vs CT组58%。
- 4个月时达到安全性标准的患者比例:BEV组61% vs CT组71%。
- 中位无进展生存期:BEV组9.7个月 vs CT组7.8个月。
- 中位总生存期:BEV组21.7个月 vs CT组19.8个月。
- 36个月总生存率:BEV组27% vs CT组10.1%。
关键数值与推荐
- 研究预设:若≤20%患者满足疗效标准则判定治疗无效,若≤40%患者满足安全性标准则判定不安全。
- BEV组与CT组分别有50%与58%的患者达到疗效标准,61%与71%的患者达到安全性标准,均超过预设阈值。
临床怎么用
- 对于≥75岁未经治疗的转移性结直肠癌患者,贝伐珠单抗联合化疗(LV5FU2、FOLFOX或FOLFIRI)在本研究中显示出可接受的安全性及疗效。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic colorectal cancer frequently occurs in elderly patients. Bevacizumab in combination with front line chemotherapy (CT) is a standard treatment but some concern raised about tolerance of bevacizumab for these patients. The purpose of PRODIGE 20 was to evaluate tolerance and efficacy of bevacizumab according to specific end points in this population. PATIENTS AND METHODS: Patients aged 75 years and over were randomly assigned to bevacizumab + CT (BEV) versus CT. LV5FU2, FOLFOX and FOLFIRI regimen were prescribed according to investigator's choice. The composite co-primary end point, assessed 4 months after randomization, was based on efficacy (tumor control and absence of decrease of the Spitzer QoL index) and safety (absence of severe cardiovascular toxicities and unexpected hospitalization). For each arm, the treatment will be consider as inefficient if 20% or less of the patients met the efficacy criteria and not safe if 40% or less met the safety criteria. RESULTS: About 102 patients were randomized (51 BEV and 51 CT), median age was 80 years (range 75-91). Primary end point was met for efficacy in 50% and 58% and for safety in 61% and 71% of patients in BEV and CT, respectively. Median progression-free survival was 9.7 months in BEV and 7.8 months in CT. Median overall survival was 21.7 months in BEV and 19.8 months in CT. The 36-month overall survival rate was 27% in BEV and 10.1% in CT. Severe toxicities grade 3/4 were mainly non-hematologic toxicities (80.4% in BEV, 63.3% in CT). CONCLUSION: Bevacizumab combined with CT was safe and efficient. Both arms met the primary safety and efficacy criteria.
引用
- Aparicio T, Bouché O, Taieb J, et al. Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol. 2018. PMID: 29045659. doi:10.1093/annonc/mdx529
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。